Redpoint Investment Management’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-3,424
Closed -$260K 643
2022
Q1
$260K Buy
+3,424
New +$300K 0.03% 576

Other funds holding TXG

Redpoint Investment Management's TXG Position: Q2 2022 in Review

Redpoint Investment Management sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 3,424 shares — an estimated $260K sold.

Redpoint Investment Management first reported a position in TXG in Q1 2022 and held it in 1 quarter. The position peaked at $260K in Q1 2022. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Redpoint Investment Management reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Redpoint Investment Management sold 3,424 10x Genomics shares in Q2 2022, an estimated $260K.
  • Redpoint Investment Management first reported a position in 10x Genomics in Q1 2022 and held it in 1 quarter.
  • Redpoint Investment Management's 10x Genomics position peaked at $260K in Q1 2022.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Redpoint Investment Management's 13F filing for Q2 2022, filed 8 Jul 2022.